Kamada Ltd. (NASDAQ:KMDA) Short Interest Update

Kamada Ltd. (NASDAQ:KMDA) was the recipient of a significant increase in short interest in January. As of January 15th, there was short interest totalling 23,200 shares, an increase of 33.3% from the December 31st total of 17,400 shares. Currently, 0.1% of the shares of the stock are sold short. Based on an average daily trading volume, of 63,600 shares, the days-to-cover ratio is currently 0.4 days.

Hedge Funds Weigh In On Kamada

A hedge fund recently bought a new stake in Kamada stock. Plato Investment Management Ltd bought a new position in Kamada Ltd. (NASDAQ:KMDA) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 21,785 shares of the biotechnology company’s stock, valued at approximately $117,000. Hedge funds and other institutional investors own 20.38% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “buy” rating and set a $11.00 target price on shares of Kamada in a research report on Friday, January 10th.

Kamada Price Performance

Kamada stock traded up $0.02 during mid-day trading on Friday, reaching $6.73. 45,552 shares of the company traded hands, compared to its average volume of 154,608. Kamada has a 52-week low of $4.74 and a 52-week high of $8.00. The firm has a market capitalization of $386.84 million, a price-to-earnings ratio of 24.04, a P/E/G ratio of 0.86 and a beta of 0.98. The firm’s 50 day moving average price is $6.42 and its 200 day moving average price is $5.86.

About Kamada

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.